CHENGDU, China, Feb. 7 TianyinPharmaceutical, Inc., (OTC Bulletin Board: VSCO), a manufacturer and supplierof modernized traditional Chinese medicine (TCM) based in Chengdu, China,today announced that Mr. Stewart Lor, a member of the Board of Directors, willhost a conference call to update shareholders on the 2008 second quarterfinancial results.
The conference call will take place at 4:15 p.m. EST, on Thursday,February 14th, 2008. Interested participants should call 800-762-8908 withinthe United States, or US + 1-480-629-1990 if calling internationally. It isadvisable to dial in approximately 5-10 minutes prior to 4:15 p.m. EST. Therewill be a playback available until March 15, 2008. To listen to the playback,please call 800-406-7325 from within the United States, or US +1 303-590-3030internationally. Please use pass code 3843464 for the replay.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by currentmanagement team in August 2003. It has a comprehensive product portfolio of34 modernized TCMs in the market, 22 of which are listed in the highlyselective National Medicine Catalog of the National Medical Insurance Program.Tianyin owns and operates two GMP manufacturing facilities and an R&D platformsupported by leading Chinese academic institutions. The Company has apipeline of 51 pharmaceutical products pending approval. Tianyin has anextensive nationwide distribution network throughout China with a sales forceof 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Provincewith two manufacturing facilities and a total of 869 employees. Tianyinachieved revenue of $20.4 million and net income of $3.95 million in FY2007ending June 30, 2007.
Safe Harbor Statement
The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.
SOURCE Tianyin Pharmaceutical, Inc.